摘要
众多研究表明,宫颈癌属于免疫原性疾病,免疫逃逸机制与其发生及进展密切相关。近年来,关于程序性死亡受体-1(PD-1)及程序性死亡配体-1(PD-L1)的靶向及免疫治疗在改善恶性肿瘤患者临床疗效中取得了一定进展,明确了PD-1/PD-L1在肿瘤免疫逃逸中扮演了重要角色,并且其与化疗耐药性也存在密切关系。全文对PD-1/PD-L1在宫颈癌化疗耐药中的作用机制进行综述,旨在为耐药的宫颈癌患者临床治疗提供参考依据。
Many studies have shown that cervical cancer is an immunogenic disease,and the immune escape mechanism is closely related to its occurrence and development.In recent years,immunotherapy with programmed cell death protein 1(PD-1)and its ligand PD-L1 have made some progress in improving the clinical efficacy of patients with malignant tumors.It has been clarified that PD-1/PD-L1 plays an important role in tumor immune escape and is closely related to chemotherapy resistance.This paper reviews the mechanism of PD-1/PD-L1 in chemotherapy resistance of cervical cancer,aiming to provide reference for clinical treatment of drug-resistant cervical cancer patients.
作者
王可可
戴文砚
王金华
WANG Ke-ke;DAI Wen-yan;WANG Jin-hua(The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Nanjing 210009,China)
出处
《肿瘤学杂志》
CAS
2023年第5期386-393,共8页
Journal of Chinese Oncology
基金
江苏省医学重点人才(2016KJQWZDRC-02)
